Drug Discovery

Can Merck’s Clesrovimab Revolutionize RSV Prevention in Infants?
Research & Development Can Merck’s Clesrovimab Revolutionize RSV Prevention in Infants?

Respiratory syncytial virus (RSV) has long been a formidable challenge, particularly for infants and older adults. Characterized by cold-like symptoms, RSV can sometimes escalate into severe respiratory conditions necessitating hospitalization. Nearly every child is exposed to RSV by the age of

AbbVie Wins FDA Approval for Continuous Parkinson’s Therapy Vyalev
Research & Development AbbVie Wins FDA Approval for Continuous Parkinson’s Therapy Vyalev

AbbVie, renowned for its portfolio of groundbreaking treatments, has achieved a major milestone with the FDA's approval of Vyalev, a novel combination therapy aimed at providing extended movement control for patients with advanced Parkinson’s disease. The approval represents more than just a t

Can Sage Therapeutics Revamp Its Strategy Amidst Challenges?
Research & Development Can Sage Therapeutics Revamp Its Strategy Amidst Challenges?

Sage Therapeutics, a biopharmaceutical company specializing in brain health medications, finds itself at a pivotal moment. Facing financial strains and developmental hurdles, the company is taking significant steps to realign its strategy, including layoffs, leadership changes, and focusing on

How Will Nuclera's New Funding Revolutionize Drug Discovery?
Research & Development How Will Nuclera's New Funding Revolutionize Drug Discovery?

Nuclera, a trailblazing biotechnology company specializing in protein expression and purification, recently raised $75 million in a fresh funding round. This significant financial boost is intended to support the commercialization and global deployment of Nuclera’s eProtein Discovery™ system. The gr

How Does Proper COA Selection Influence Drug Development Success?
Research & Development How Does Proper COA Selection Influence Drug Development Success?

Clinical Outcome Assessments (COAs) play a pivotal role in the drug development process. These tools, which measure the impact of a treatment on patients' health status, encompass several types: Patient-Reported Outcomes (PROs), Clinician-Reported Outcomes (ClinROs), Observer-Reported Outcomes

Lundbeck Acquires Longboard for $2.6B to Boost Neurology Portfolio
Research & Development Lundbeck Acquires Longboard for $2.6B to Boost Neurology Portfolio

Lundbeck, the Danish drugmaker, has announced its acquisition of Longboard Pharmaceuticals for $2.6 billion, centering the deal around Longboard's promising experimental brain medicine, bexicaserin. This medicine is in late-stage clinical testing for treating developmental and epileptic

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later